Eccogene Received $50 Million Milestone From AstraZeneca
The payment follows the launch of a global Phase 3 clinical trial for the weight-loss drug candidate elecoglipron.
Updated on Sept. 29, 2026 in Diabetes
Live Poll
Do you trust pharmaceutical firms to prioritize long-term patient health when developing new obesity treatments?
Eccogene has secured a $50 million milestone payment from its partner AstraZeneca following the initiation of a global Phase 3 clinical program for elecoglipron. The drug is a once-daily oral GLP-1 receptor agonist currently under development for obesity and type 2 diabetes.
Why it matters
The payment marks a significant development in the partnership as the companies push their GLP-1 candidate into advanced clinical testing. It underscores the high-stakes competition within the pharmaceutical industry to develop oral alternatives for weight loss and diabetes management.
Phase 2b trials for elecoglipron demonstrated an 11.8% weight loss at 36 weeks and a 1.9% HbA1c reduction at 26 weeks. To date, Eccogene has earned $295 million under its collaboration with AstraZeneca.
The players
Eccogene
Eccogene is a biotechnology company with corporate operations in Boston and Shanghai that focuses on metabolic disease therapies.
AstraZeneca
AstraZeneca is a global pharmaceutical corporation that develops and markets a wide range of medical treatments and clinical drug candidates.
The details
The newly initiated Phase 3 program for elecoglipron includes the Embold trials for patients with obesity or overweight status and the Eluminate trials for those with type 2 diabetes. The collaboration was established in November 2023 with an initial upfront payment of $185 million.
Timeline
November 2023: Eccogene entered a licensing agreement with AstraZeneca.
September 29, 2026: Eccogene announced the receipt of the milestone payment.
Health Landscape
The development of elecoglipron represents the broader shift toward oral, once-daily GLP-1 receptor agonists to address the limitations of injectable weight-loss therapies. This initiative positions AstraZeneca to compete more effectively against current market leaders in the metabolic treatment sector.
The progress of this Phase 3 trial may eventually offer patients an oral, once-daily alternative to injectable weight-loss and diabetes medications. Individuals currently managing these conditions should continue consulting their healthcare providers about existing, approved therapies.
The takeaway
The transition of elecoglipron into Phase 3 trials marks a pivot from early-stage testing to large-scale verification of safety and efficacy. Patients tracking this drug should understand that Phase 3 is a final, lengthy stage of clinical research before a potential FDA submission.
Further reading
For additional context on the evolution of metabolic health treatments, visit the Diabetes section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust pharmaceutical firms to prioritize long-term patient health when developing new obesity treatments?
